---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005268"
form_type: "8-K"
ticker: null
cik: "0001008586"
company_name: "STREAMLINE HEALTH SOLUTIONS INC."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T06:18:32.100995+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Streamline Health raises ~$4.5M, modifies credit facility, appoints two directors

## Summary
- Aggregate gross proceeds ~$4.5M: $4.4M notes bearing 15% interest (maturity 8/7/26) and $100K common stock; warrants for 4,052,631 shares at $0.38 strike.
- Modified Western Alliance Bank credit facility: updated debt-to-EBITDA thresholds, removed minimum cash and max debt-to-ARR covenants, added quarterly adjusted EBITDA targets.
- Appointed CEO Benjamin Stilwill and Matthew Etheridge to board effective Feb 7, 2024; board expanded to seven.
- Company expects liquidity to enable adjusted EBITDA breakeven run rate of $15.5M installed SaaS ARR in H2 fiscal 2024.

## SEC filing metadata
- accession: 0001493152-24-005268
- form_type: 8-K
- cik: 0001008586
- company_name: STREAMLINE HEALTH SOLUTIONS INC.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1008586/000149315224005268/0001493152-24-005268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1008586/000149315224005268/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005268
- JSON: https://secwatch.observer/filing/0001493152-24-005268.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005268.txt

## Key facts
- Debt Financings
  STREAMLINE HEALTH SOLUTIONS INC. amended credit facility with Western Alliance Bank.
  - Instrument: credit facility
  - Counterparty: Western Alliance Bank
  - Event: amendment
  source text: On February 7, 2024, the Company and certain of its subsidiaries entered into a Third Modification and Waiver (the “Third Modification”) to Second Amended and Restated Loan and Security Agreement (the “Loan and Security Agreement”) with WAB.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1008586/000149315224005268/0001493152-24-005268-index.htm
- Executive change
  Matthew Etheridge was appointed as Director at STREAMLINE HEALTH SOLUTIONS INC..
  - Action: appointed
  - Role: Director
  source text: appointed Benjamin L. Stilwill and Matthew Etheridge to serve as directors of the Company, effective as of the closing of the Debt Private Placement on February 7, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1008586/000149315224005268/0001493152-24-005268-index.htm
- Executive change
  Benjamin L. Stilwill was appointed as Director at STREAMLINE HEALTH SOLUTIONS INC..
  - Action: appointed
  - Role: Director
  source text: appointed Benjamin L. Stilwill and Matthew Etheridge to serve as directors of the Company, effective as of the closing of the Debt Private Placement on February 7, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1008586/000149315224005268/0001493152-24-005268-index.htm
- Material Agreements
  STREAMLINE HEALTH SOLUTIONS INC. entered into Securities Purchase Agreement with certain accredited investors, including certain directors and officers of the Company (collectively, the "Investors") valued at aggregate principal amount of $4.4 million (effective 2024-02-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors, including certain directors and officers of the Company (collectively, the "Investors")
  - Value: aggregate principal amount of $4.4 million
  - Effective: 2024-02-01
  source text: On February 1, 2024, Streamline Health Solutions, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors, including certain directors and officers of the Company (collectively, the “Investors”), pursuant to which the Company agreed to sell to the Investors unsecured subordinated promissory notes (the “Notes”) in the aggregate principal amount of $4.4 million and warrants
  evidence_url: https://www.sec.gov/Archives/edgar/data/1008586/000149315224005268/0001493152-24-005268-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.